Danaher (DHR) PT Raised to $290 at TD Cowen

TD Cowen analyst Dan Brennan raised the price target on Danaher (NYSE: DHR) to $290.00 (from $280.00) while maintaining a Buy rating.

The analyst commented, "DHR traded up 7% post-Q1 results and we see more to go. Though the '24 guide was largely maintained, we see a clear upside bias as the Bioproduction (BP) inflection is beginning, plus Dx and Life Sci also showed strength. Our Buy thesis, based in part upon sales acceleration in high margin BP segment enabling EPS upside, was strengthened with 1Q results."

You May Also Be Interested In

• salesforce.com (CRM) PT Raised to $300 at TD Cowen
• Science Applications (SAIC) PT Raised to $123 at UBS
• UBS Downgrades Shanghai Chicmax Cosmetic (2145:HK) to Neutral